Targeting lethal minimal residual disease in small cell lung cancer.
In the last three decades, treatment for small cell lung cancer has improved with advances in chemotherapy and radiotherapy. Almost all patients respond initially to standard chemotherapy, and some patients with limited stage disease are cured with the combination of chemotherapy and thoracic irradiation. Nonetheless, the majority of patients will experience lethal relapse from chemotherapy-resistant micrometastatic disease, and this has resulted in poor long-term survival for most patients. Addressing the problem of relapse requires unique approaches to eliminating minimal residual disease. This review will focus on the detection of minimal residual disease as well as strategies with which to treat it, including matrix metalloproteinase inhibitors, tyrosine kinase inhibitors, and vaccine therapy.
Patel
Jyoti D
JD
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA.
Krug
Lee M
LM
Azzoli
Christopher G
CG
Gomez
Jorge
J
Kris
Mark G
MG
Miller
Vincent A
VA
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000175:diagnosis / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D061965:Matrix Metalloproteinase Inhibitors; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D014612:Vaccines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D014612:Vaccines; D011505:Protein-Tyrosine Kinases